COPD

This new data on dupilumab demonstrates the drug’s potential usefulness in treating type 2 inflammation, a role which is central to respiratory diseases including COPD.

This portion of Mosher’s interview featured a discussion about the future of respiratory care following the updates on the guidelines for pulmonary rehabilitation delivery.

During this segment of his interview, Mosher discussed center-based pulmonary rehabilitation versus telerehabilitation and other elements from the updated guidelines.

In this discussion, Dr. Mosher shared several key insights on the recently updated clinical practice guidelines for pulmonary rehabilitation delivery.

This new data indicates opportunities which may have been missed for initiation of fracture prevention for elderly individuals treated with oral corticosteroids.

"Our research is unique in its attempt to describe a high-need, high-cost patient population who might benefit from increased monitoring or intervention," Dr. Ann Cameron says.

"High-risk patients are more likely to experience comorbid conditions and are more likely to use COPD medications and oxygen, reflecting a higher disease burden," Dr. Ann Cameron explains.

“We all know that exacerbations are the most costly disease impact of COPD,” study investigator Dr. Charlie Strange says.

Data indicates that addressing mood disorders in patients not only improves mood symptoms but also demonstrates positive effects on certain cardiac events, suggesting benefits for both mental and physical well-being.

Key opinion leaders at ATS 2023 urge physicians to treat more than just symptoms in patients with COPD and consider mood disorders and cardiac comorbidities.

In an interview at ATS 2023, Dr. Rutland stresses the importance of studying the immune system's response to various diseases, emphasizing the potential impact of pipeline molecules.

Though still not in abundance on the market, ICS/LAMA/LABA triple-therapy single inhaler treatment options are becoming more valued for COPD exacerbation and comorbid disease risk.

Dr. Rutland emphasizes the importance of understanding cellular communication and its potential to manipulate disease processes for patient benefit, including the observed link between ILD, inflammation, scarring, and pulmonary hypertension.

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

An analysis of the COPDGene Study presented at ATS 2023 suggests presence of mucus plugs in medium- to large-sized airways were associated with an increased risk of mortality in adjusted models.

At West Penn Hospital, the harmonica program, currently in the pilot phase, aims to demonstrate its benefits in improving respiratory symptoms, reducing exacerbations, and enhancing patients' quality of life.

"Playing the harmonica has a therapeutic effect because of the pursed lip breathing technique it requires," Dr. Becky Jordan says in an interview.

On the latest Lungcast, Kalhan reviewed a 2018 paper he and colleagues penned on the need to establish phenotypes of chronic lung disease progression—such as what cardiology has done with LDL-C for heart attacks.

Insomnia shows associations with higher rates of outpatient visits, hospitalizations, and fills for medications, longer hospital length of stay, and higher hospitalization costs.

In the latest Lungcast, a pair of experts considered the marriage of low-dose CT scanning and machine learning to optimize lung disease interception.

New meta-analysis show patient demographics—as well as their pre-existing comorbidities and COVID-19 vaccination status—may significantly define their risk of long-term conditions.

Data also show significant improvements in quality of life and respiratory symptoms in patients with evidence of type 2 inflammation who were treated with dupilumab.

A one-of-its-kind assessment of 8 decades' worth of UK data show a lower respiratory tract infection by age 2 increases risk of premature adult death by 93%.

The new analysis on the screening tool in primary care patients with COPD highlights the need for further research to optimize CAPTURE's performance and impact on clinical outcomes.

Frailty is a serious issue in hospitalized patients and is associated with increased morbidity and mortality. However, a recent study suggests that the Hospital Frailty Risk Score (HFRS), may not be effective in identifying frailty in hospitalized COPD patients compared to the bedside Clinical Frailty Scale (CFS).

The analysis uses patient data from SPIROMICS, followed by an external validation with the results from COPDGene.

The medication was approved for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.

Neither intervention group demonstrated any significant improvements in intensity of chronic breathlessness after taking regular, low-dose, extended-release morphine.

These data support web-based self-management for individuals with COPD with an objective, clinically relevant, short-term increase in physical activity levels compared to usual care.

“From this study it makes sense that the (icenticaftor) 300mg dose has a benefit-risk profile to further study the clinical benefits,” Dr. Frits Franssen, lead investigator, said at ERS Congress 2022.